Pneumococcal conjugate vaccine formulations
AssigneeMerck Sharp & Dohme Corp.
InventorsWilliam J. Smith, Cecilia Giovarelli, Denise K. Nawrocki
Life of this patent
Estimating the term…
Abstract
The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.
Claims36
A formulation comprising (i) a 15-valent pneumococcal conjugate composition consisting essentially of S. pneumoniae polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F and 33F, each conjugated to either CRM197 or diphtheria toxin fragment B (DTFB);
- (ii) a pH buffered saline solution having a pH in the range from 5.0 to 7.5;
- (ii) an aluminum salt;
- and (iv).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A formulation comprising a 15-valent pneumococcal conjugate composition consisting essentially of S. pneumoniae polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F and 33F conjugated to CRM197;
- 20 mM Histidine pH 5.8;
- 150 mM NaCl;
- 250 μg/mL, APA;
- and 0.2% w/v polysorbate 20.
A formulation comprising a 15-valent pneumococcal conjugate composition consisting essentially of S. pneumoniae polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F and 33F conjugated to CRM197;
- 20 mM Histidine pH 5.8;
- 150 mM NaCl;
- 250 μg/mL APA;
- and 0.2% w/v polysorbate 20;
- formulated as a dosage form containing 4 μg/mL of each polysaccharide, except for the 6B polysaccharide which is at 8 μg/mL;
- and about 64 μg/mL CRM197 carrier protein.
Dependencies are inferred from the claim text.